StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) company profile

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)

Close on Nov 17, 2026Market cap $3.73BP/E –Yield –

About Tango Therapeutics

Pharmaceutical Preparations, SIC 2834

Tango Therapeutics, Inc. is a precision oncology company focused on the development of novel therapies for patients diagnosed with genetically defined or biomarker-driven cancers. Utilizing synthetic lethal targeting designed to spare normal cells, the company discovers and advances oncology treatments targeting pathways such as MTAP-deleted cancers. Its clinical and research programs include therapeutic candidates such as vopimetostat (TNG462), TNG456, and other targeted molecules, which it develops as single agents or in combination therapies alongside strategic collaborators.

The company operates in the United States and maintains its principal executive offices in Boston, Massachusetts. Its facilities include leased properties located at 201 Brookline Avenue. Tango Therapeutics engages with clinical trial sites, research organizations, and manufacturing partners across domestic jurisdictions to advance its preclinical and clinical-stage pharmaceutical pipeline.

Summary of the business section of Tango Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Tango Therapeutics, Inc.
Founded
2020
Headquarters
Boston, MA
Address
201 Brookline Avenue, Suite 901 02215
Phone
(857) 320-4900
Employees
137, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
TNGX
Exchange
Nasdaq
IPO date
Sep 4, 2020
Shares outstanding
169M, Aug 4, 2026
Public float
$528.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
5-for-2, Nov 9, 2021
SEC CIK
1819133
CUSIP
87583X109
ISIN
US87583X1090
FIGI
BBG00WFDDRS0
Share class FIGI
BBG00WFDDSK6
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Barbara WeberDirector, Executive Chair1,629,587
Malte PetersPresident & CEO, Director367,500
Adam CrystalPresident, R&D115,743
Jessica NewcombPrincipal Accounting Officer52,090
Matthew GallChief Financial Officer40,000
Daniella BeckmanChief Financial Officer184,297
Douglas BarryGeneral Counsel66,014
Robert AzelbyDirector5,740
Lesley Ann CalhounDirector16,500
John B. KetchumDirector24,937
Sung LeeDirector22,870
Mace RothenbergDirector41,500
Alexis BorisyDirector17,500

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.82M$10.11M$1.44M––
FY2024$6.54M-$3.08M$3.01M––
FY2023$3.39M$8.14M$2.13M––
FY2022$4.68M-$2.85M$1.67M––

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Barbara Weber, M.D.
Executive Chairman
$697.95K$308.10K$1.28M$524.25K$18.37K$2.82M-57%
Daniella Beckman
Former Chief Financial Officer
$502.88K$76.01K$314.62K$244.12K$18.16K$1.16M-63%
Adam Crystal, M.D., Ph.D.
President of Research and Development
$588.64K$154.27K$638.60K$321.47K$18.10K$1.72M-54%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Sep 4, 2020
Offer price
$10.00
Securities offered
14,500,000
Gross proceeds
$145.00M
Exchange
Nasdaq
First trading day
Sep 3, 2020
First-day close
$10.23+2.3%
Lock-up ends (est.)
Mar 2, 2021

“This is the initial public offering of our common stock, $0.0001 par value, at an initial public offering price of $10.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 137 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 13, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 13, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 9, 2021Name changeName changed from BCTG Acquisition Corp. to Tango Therapeutics, Inc.
Apr 20, 2021MergerRegistration of securities for a merger or exchange offer (S-4)
Sep 4, 2020IPOInitial public offering priced (424B4 prospectus)
Sep 2, 2020ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?